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Objective: To assess the prevalence of kidney failure in patients from a primary care centre
in  a basic healthcare district with laboratory availability allowing serum creatinine mea-
surements.
Design: An observational descriptive cross-sectional study.
Data sources: A basic healthcare district serving 23,807 people aged ≥ 18 years.
Results: Prevalence of kidney failure among 17,240 patients having at least one laboratory
measurement available was 8.5% (mean age 77.6 ± 12.05 years). In 33.2% of such patients an
occult kidney failure was found (98.8% were women).
Prevalence of chronic kidney failure among 10,011 patients having at least 2 laboratory
measurements available (≥3 months apart) was 5.5% with mean age being 80.1 ± 10.0 years
(most severely affected patients were those aged 75–84); 59.7% were men and 76.3% of cases
were in stage 3. An occult kidney failure was found in 5.3% of patients with women being
86.2%  of them (a glomerular ﬁltration rate < 60 mL/min was estimated for plasma creatinine
levels of 0.9 mg/dl or higher).
Conclusions: Comparison of present ﬁndings to those previously reported demonstrates the
need for further studies on the prevalence of overall (chronic and acute) kidney failure in
Spain in order to estimate the real scope of the disease. Primary care physicians play a
critical role in disease detection, therapy, control and recording (in medical records). MDRD
equation is useful and practical to estimate glomerular ﬁltration rate.©  2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is anopen access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Repetición  de  la  medición  de  creatinina  sérica  en  atención  primaria:  no
todos  tienen  insuﬁciencia  renal  crónica
Palabras clave:
Enfermedad renal crónica
Insuﬁciencia renal
Insuﬁciencia renal crónica
r  e  s  u  m  e  n
Objetivo: Evaluar la prevalencia de la insuﬁciencia renal en los pacientes de un centro médico
de  un área básica de salud que disponen de determinaciones analíticas de creatinina sérica.
Disen˜o:  Estudio descriptivo observacional transversal.
Fuentes de datos: Área básica de salud con 23.807 usuarios de ≥18 an˜os de edad.
Resultados: La prevalencia de la insuﬁciencia renal entre los 17.240 pacientes que disponían
de,  al menos, una analítica fue del 8,5%, con una media de edad de 77,6 ± 12,05 an˜os. Un
33,2%  de los afectados presentaba una insuﬁciencia renal oculta, siendo un 98,8% mujeres.
La  prevalencia de la insuﬁciencia renal crónica entre los 10.011 pacientes que disponían de
al  menos 2 analíticas separadas por ≥ de 3 meses fue del 5,5%, siendo su media de edad
de  80,1 ± 10,0 an˜os (el grupo más afectado fue el de 75 a 84 an˜os), un 59,7% hombres, y un
76,3% de los casos con estadio 3. Un 5,3% de los afectados presentaban una insuﬁciencia
renal  oculta, el 86,2% de estos eran mujeres (se calculaba un ﬁltrado glomerular < 60 mL/min
ya  con niveles de creatinina plasmática de 0,9 mg/dl).
Conclusiones: La comparación de los resultados actuales con los previos reportados pone
de  maniﬁesto la necesidad de realizar nuevos estudios de prevalencia de la insuﬁciencia
renal global, crónica y oculta en Espan˜a para poder valorar el alcance real de la enfermedad.
El  médico de atención primaria juega un papel fundamental en la detección, tratamiento,
control y registro de la enfermedad (en la historia clínica). La fórmula MDRD resulta útil y
práctica para estimar el ﬁltrado glomerular.
© 2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Chronic kidney disease (CKD) is an important, growing world-
wide healthcare problem due to population ageing and to
the increase in its risk factors. Its high cardiovascular (CV)
and total morbidity and mortality, high healthcare costs
and important social implications make early diagnosis and
treatment necessary. To do so, it is necessary for medical pro-
fessionals at all levels of the healthcare system to be aware of
this problem. Multidisciplinary clinical guidelines should also
be established for the management of these patients and their
subsequent referral to nephrologists.
According to the K/DOQI guidelines, CKD is classiﬁed
into stages of severity based on glomerular ﬁltration rate
(GFR) and the existence of kidney lesions of ≥3 months1,2;
more recently, the detection of signiﬁcant albuminuria has
been added as a criteria.2 In daily clinical practice other
terms are still frequently used, like “renal failure” (RF)
(GFR < 60 mL/min/1.73 m2: corresponds with stages 3–5) and
“chronic renal failure” (CKD) (RF for ≥3 months). “Occult renal
disease” (ORD) refers to the situation in which RF occurs with
normal serum creatinine levels.
In Spain, numerous studies of prevalence of RF (GFR equiv-
alent to stages 3–5) done in different populations lead to
non-uniform results. Those done in the general population
≥18 years treated in primary care clinics (PC) reported rates of
7% (43.5% were ORD),3 14.5%,4 16.4% (26.1% ORD)5 and even21.3% in the EROCAP study (the largest done in our country on
CKD in PC, with 7202 patients with 37.3% ORD)6; in patients
older than 64 and 70, prevalences of ORD were 21.2 and 33.7%
respectively.6,7
Multiple studies and meta-analyses have conﬁrmed that
reduced GFR is an important risk for CV and total mor-
bidity/mortality. CV risk factors and established CV disease
lead to CKD and this, in turn, leads to CV disease, which
is the ﬁrst cause of death.8–14 This is why patients with
CRF are at high or very high CV risk, and many  authors
consider CRF equivalent to heart disease and, therefore, eli-
gible for therapeutic measures and objectives for secondary
CV prevention.14–16 CRF screening is currently recommended,
especially in high-risk populations15; the best screening
method uses GFR estimation based on different formulas
(especially the MDRD equation and, more  recently, the CKD-
EPI2).
Objectives
The main objective of the study was to evaluate CRF and ORD
prevalence in patients from Primary care (PC) medical clinics
based on the same healthcare district (BHD). Patients evalu-
ated had serum creatinine data recorded in their medical ﬁles.
The prevalence of RF was likewise determined.
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aterial  and  methods
tudy  design
urs is a cross-sectional, observational, descriptive study
ith a retrospective component carried out in a BHD with
4,436 potential users, 23,807 of which were ≥18 years of age.
ncluded in the study were 17,240 of these patients who had
t least one blood test with creatinine levels. The study period
as from October 2001 to April 2014.
ariables
he data collected included demographic variables, informa-
ion from the computerised PC patient ﬁles and laboratory
arameters. The serum creatinine determination method
sed was Jaffé kinetic method. The abbreviated MDRD-4 for-
ula was used to estimate GFR.
For this study, we  considered that the patient had RF if the
FR was <60 mL/min/1.73 m2, CRF if the RF persisted on 2 anal-
ses separated by ≥3 months, and ORD if the RF or CRF had
ormal serum creatinine levels (estimated as <1.2 mg/dL in
omen and <1.3 mg/dL in men).
As the study was cross-sectional but had a retrospective
omponent, the index Cr was the last available at the time of
Patients ≥18 yrs,
n=23 807 (97.4%)
CRF,
n=548 (5.5%)
≥2 workups,
≥3 months apart,
n=10 011 (58.1%)
≥1 workup,
n=17 240 (72.4%)
No workup,
n=6567 (27.6%)
ORD,
n=29 (5.3%)
Women,
86.2%
Men,
13.8%
BHD 24,436
users
RF
n=1243 (
Fig. 1 – Study ﬂowchart RF: renal failure; CRF: chr(4):395–402 397
the study, obtained at the clinic and the previous Cr was from
the preceding test by more  that 3 months.
Statistical  analysis
Using SPSS version 16.0 software, a descriptive study was cre-
ated to express the results of the quantitative variables as
means and standard deviation (X ± SD); the qualitative vari-
ables were expressed as percentages.
Results
First, we studied 17,240 (72.4%) of all patients of the BHD who
were ≥18 years of age who had been treated at the medical
centre and had at least one recorded analytical determination
of serum creatinine level. Mean age was 57.8 ± 19.1, versus a
mean age of 39.5 ± 14.6 for those patients who  did not have
lab results available in their ﬁles. Among these patients, 1474
(8.5%) presented RF with a mean age of 77.6 ± 12.05 (range
20–102 years). Out of all these cases of RF, 489 (33.2%) repre-
sented ORD, with 483 (98.8%) cases in women and 6 (1.2%) in
men  (Fig. 1). When we reviewed the list of pathologies recorded
in the computerised ﬁles of the 1474 patients with RF, 34.1%
had the diagnostic code for CRF.
RF,
n=1474 (8.5%)
ORD,
n=489 (33.2%)
Women
98.8%
Men
13.8%
,
12.4%)
onic renal failure; ORD: occult renal disease.
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Table 1 – CRF by age groups and sex.
Age groups (yrs) CRF n (%) No CRF n (%) Total CRF prevalence (%)
Men Women Men Women
<65 29 (80.6) 7 (19.4) 2103 (43.3) 2758 (56.7) 4897 0.7
65–74 82 (78.8) 22 (21.2) 992 (45.5) 1189 (54.5) 2285 4.5
75–84 128 (57.9) 93 (42.1) 685 (40.8) 993 (59.2) 1899 11.6
≥85 88 (47.1) 99 (52.9) 253 (34.1) 490 (65.9) 930 20.1
Total (sexes) 327 (59.7) 221 (40.3) 4.033 (42.6) 5430 (57.4) 10,011
TOTAL 548 (5.5) 9463 (94.5) 10,011
CRF, chronic renal failure.Second, we  selected the group of patients of the BHD ≥ 18
years of age who had at least 2 serum creatinine values
obtained separated by ≥3 months so the prevalence of RF
and CRF was determined. This condition was met  by 10,011
patients with a mean time elapsed between the 2 blood
tests of 13.8 ± 10.3 months (range 3–98.4 months). Initially, we
only contemplated the last available Creatinine. We found
that 1243 (12.4%) presented RF (Fig. 1); by stages: 88.7% were
stage 3, 9% were stage 4 and 2.2% stage 5. Review of med-
ical charts revealed that 36.8% had the diagnostic code for
CRF (this code was also present in 6.3% of the patients with
GFR > 60 mL/min/1.73 cm2).
Then, we  analysed the latest blood tests as well as the pre-
vious test available that was ≥3 months prior. It was found
that 548 (5.5%) patients presented CRF, with a mean age
of 80.1 ± 10.0 (range 24–99 years). By sex, 327 (59.7%) of the
affected patients were men; by age groups, the greatest preva-
lence (40.3%) was between 75 and 84 years (Table 1); by stages,
76.3% of the cases were stage 3 CRF (Table 2). Of all the CRF, 29
(5.3%) were ORD, 25 (86.2%) of which were in women; mean age
was 85.4 ± 6.7 and 4 (13.8%) cases were men  (Fig. 1). The creati-
nine level for a GFR < 60 mL/min was 0.9 mg/dL in women and
1.2 mg/dL in men. Upon review of the computerised medical
charts of the patients with CRF, we observed that 67.7% had
the diagnostic code for CRF.
Table 2 – CRF by stages and sex.
CRF stage Men n (%) Age (yrs) (X ± DE) Wome
3 261 (79.8) 
78.2 ± 10.1 
3a 166 (50.8) 
77.5 ± 10.3 
3b 95 (29.0) 
79.4 ± 9.5 
4 48 (14.7) 
79.3 ± 8.6 
5 18 (5.5) 
74.2 ± 12.1 
Total 327 (59.7) 
78.2 ± 10.0 
CRF, chronic renal failure.The analytical parameters registered in the patients with
CRF are shown in Table 3. The LDL cholesterol (c-LDL) levels
were determined depending on the stage of renal involve-
ment: 51.2% of patients presented levels < 100 mg/dL and
15.5% < 70 mg/dL (Table 4).
Discussion
The prevalence of RF detected in the population of adult
patients who were treated at a BHD medical centre and had
at least one lab test with creatinine was 8.5%, and 33.2% of
which were ORD. Nonetheless, we found that the prevalence
of CRF was 5.5%, although this percentage increased to 10% in
patients over the age of 64 and to 20.1% in those over the age
of 85; only 5.3% of cases had ORD.
When data reported by other authors about the epidemiol-
ogy of renal disease in Spain was reviewed and compared with
our series, we observed that the main limitation of all previ-
ous CRF prevalence studies was that they are cross-sectional
and based on the estimation of GFR from a single blood
test. Thus, it is not possible to differentiate between patients
with transitory kidney involvement (acute intercurrent dis-
ease, nephrotoxic drugs, etc.) and those with established
CRF.
n n (%) Age (yrs) (X ± DE) Total n (%) Age (yrs) (X ± DE)
157 (71.1) 418 (76.3)
83.4 ± 7.3 80.2 ± 9.5
48 (21.8) 214 (39.0)
81.9 ± 8.2 78.5 ± 10.0
109 (49.3) 204 (37.3)
84.0 ± 6.8 81.9 ± 8.5
56 (25.3) 104 (18.9)
83.0 ± 11.0 81.3 ± 20.1
8 (3.6) 26 (4.8)
71.9 ± 21.4 73.5 ± 15.1
221 (40.3) 548 (100.0)
82.8 ± 9.3 80.1 ± 10.0
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Table 3 – Analytical parameters registered by stages.
Variables Stage 3 Stage 3a Stage 3b Stage 4 Stage 5 Total
Creatinine (mg/dL) 1.5 ± 0.2 1.3 ± 0.1 1.6 ± 0.2 2.5 ± 0.5 5.6 ± 1.8 1.9 ± 1.1
Cholesterol (mg/dL) 176.7 ± 35.3 177.4 ± 34.6 176.0 ± 36.2 168.4 ± 38.7 154.2 ± 37.7 174 ± 36.5
c-HDL (mg/dL) 47.1 ± 12.5 46.7 ± 12.8 47.6 ± 12.1 45.2 ± 13.7 45.9 ± 17.6 46.7 ± 13.0
c-LDL (mg/dL) 104.7 ± 32.1 105.4 ± 31.2 104.0 ± 33.2 97.8 ± 35.9 73.6 ± 28.3 101.9 ± 33.3
Glucose (mg/dL) 106.0 ± 34.1 107.4 ± 37.4 104.5 ± 30.3 108.8 ± 32.1 104.3 ± 23.7 106.4 ± 33.3
HBA1C (%) 6.1 ± 1.2 6.0 ± 1.3 6.2 ± 1.1 6.3 ± 1.4 5.4 ± 0.9 6.1 ± 1.3
Haemoglobin (g/dL) 13.0 ± 1.9 13.6 ± 1.9 12.4 ± 1.8 13.1 ± 11.8 11.0 ± 1.1 12.9 ± 5.4
r
m
o
t
t
a
m
t
e
t
t
u
n
t
i
t
l
t
e
C
o
i
s
c
T
G
c
e
a
w
b
uConsidering this limitation, we compared the different
ates of renal involvement observed after evaluating one or
ore  serum creatinine values. We  determined the prevalence
f the disease in 2 groups of patient: those with only one blood
est available and those with 2 or more.  In the ﬁrst group,
he study began by determining the prevalence of RF (global:
cute and chronic), which was 8.5% and, therefore, lower than
ost studies done in PC that range between 73–5 and 21.3% of
he EROCAP study.6 The reasons for these differences could be
xplained by different methodologies used to evaluate blood
ests, patient clinical stability, different range for normal crea-
inine levels (non standardised determination), the occasional
se of other formulas to estimate GFR and, perhaps, largest
umber of included patients.
Based on the timeframe that deﬁnes CRF that was sys-
ematically obviated in the past, the study was continued
n the second group of patients (those with ≥2 blood tests
hat were ≥3 months apart). We found that when RF preva-
ence was determined according to the latest blood test,
he resulting percentage was 12.4%. However, as could be
xpected, when 2 analyses were assessed, the prevalence of
RF dropped to 5.5%; this was presumably due to the exclusion
f transitory reductions in GFR. Nonetheless, it is surpris-
ng to observe that in patients with CRF the percentage of
tages 4 and 5 was twice as high as in RF while the per-
ent of patients in stage was slightly decreased (Table 5).
his observation is contrary to what was expected because
FR estimation using the MDRD formula requires a stable
reatinine concentration and, therefore, presents limitations
specially for GFR levels around 60 mL/min/1.73 cm2, which
re most susceptible to change in certain patients (those
ith special diets, signiﬁcantly altered muscle mass, extreme
ody mass indices, severe liver disease, etc.) and in sit-
ations of acute concomitant morbidity. Additionally, this
Table 4 – Levels of LDL cholesterol according to CRF stage.
c-LDL (mg/dl) Stage 3 n (%) Stage 4 n (
c-LDL < 100 198 (71.5) 57 (20.6
c-LDL ≥ 100 214 (81.1) 46 (17.4
Total 412 (76.2) 103 (19.0
c-LDL < 70 48 (57.1) 24 (28.6
c-LDL ≥ 70 364 (79.6) 79 (17.3
Total 412 (76.2) 103 (19.0ﬁnding, once again, demonstrates the importance of correctly
evaluating the data on epidemiology of CKD. The estima-
tion of prevalence based on a single lab test may result in
underestimation of the prevalence of more  advanced disease
stages.
Thus, the prevalence of CRF found in our series (which
is 5.5%) is the lowest reported (keeping in mind the limi-
tations when comparisons are made with previous studies).
However, it probably better reﬂects the actual situation
of CKD in the population of our series. Therefore, the
remainder of the study was centred around this group of
patients.
We observed a close relationship between CRF and age,
which is a well-known relationship, although mean patient
age in our patients (80.1 ± 10.0 years) was older than in other
reports. When analysed by age, prevalence of CRF in patients
over the age of 64 was 10% (vs. 21.2 and 33.7%, previously
reported in patients over the age of 64 and 70, respectively6,7),
but this increased to 20.1% in patients ≥85 years (Table 1).
With regards to sex, as reported by some authors, RF slightly
affected more  men  than women,5,6 although these women
patients were older.
As far as severity of CRF, most cases were mild-moderate
(stage 3, especially 3a), a fact that has also been observed in
other studies.5 This ﬁnding emphasises the opportunity of PC
physicians to diagnose CKD at early stages and, consequently,
to initiate appropriate therapies to slow the progression of
the disease and reduce CV and other complications, which
is especially effective if initiated in stages 2 and 3.15
The association of CKD, especially stages 3–5, with CV
involvement has been repeatedly demonstrated in several
populations. The greater CV morbidity and mortality of
these patients is due to the presence of a higher preva-
lence of classic CV risk factors and other factors inherent
%) Stage 5 n (%) Total n (%)
) 22 (7.9) 277 (51.2)
) 4 (1.5) 264 (48.8)
) 26 (4.8) 541 (100.0)
) 12 (14.3) 84 (15.5)
) 14 (3.1) 457 (84.5)
) 26 (4.8) 541 (100.0)
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Table 5 – Prevalence of RF (based on one serum creatinine determination) and CRF (based on 2 determinations) and their
stages in the 10,011 patients with 2 blood tests that were  ≥3 months apart.
Creatinine determinations GFR < 60 mL/min/1.73 cm2 Stages according to GFR
3 4 5
1 Blood test, n (%) 1243(12.4)  1103 (88.7) 112 (9) 28 (2.2)
2 Blood tests, n (%) 548(5.5) 418  (76.3) 104 (18.9) 26 (4.8)
GFR, glomerular ﬁltration rate.to nephropathy (altered mineral metabolism and arte-
rial calciﬁcation, endothelial dysfunction, insulin resistance,
inﬂammation, malnutrition, anaemia, etc.) in addition to
the deleterious effects of treatment and therapeutic limita-
tions typical of these patients (less use of ACE inhibitors,
beta-blockers, antithrombotics, percutaneous coronary inter-
ventions, etc.).9
Although the management and treatment of this dis-
ease have greatly advanced in recent years, compliance with
current recommendations is far from optimal in numerous
healthcare settings. The fact is that, to reduce CV events and
slow renal function loss, it is necessary to implement integral
management plans with preventive CV measures, includ-
ing lifestyle changes, diet and pharmacological treatment.
According to European recommendations for CV prevention,
patients with moderate CRF (GFR 30–59 mL/min/1.73 m2) are
considered at high CV risk, and patients with severe CRF
(GFR < 30 mL/min/1.73 m2) are very high risk. These conditions
are comparable to established ischaemic heart disease; there-
fore, it is recommended to establish objectives for secondary
CV disease prevention. Likewise, the CKD consensus docu-
ment developed by Spanish scientiﬁc societies in 2012 states
that CKD is equivalent to other coronary disorders and, there-
fore, treatment objectives are the same as in patients with
ischaemic heart disease.14,15,17–19 More  recently, a document
of the Spanish Society of Nephrology states that patients with
CKD in stages 3–5 are at high CV risk.20 Given these assess-
ments and with regards to dyslipidaemia treatment in these
patients, it is reasonable to achieve c-LDL levels <100 mg/dL
in CRF stage 3 and <70 mg/dL in CRF stages 4 and 5 (without
dialysis) by prescribing statins.14
Regarding our BHD series, to evaluate CV morbidity and
what is adequate or not for the therapeutic management
of patients with CRF, it would have been necessary to com-
pile patient medical histories, complementary tests e (ECG,
echocardiogram, other blood analyses, etc.) and treatments
that had been prescribed. However, such data collection
was not obtained because the patient data registration and
codiﬁcation in the computerised PC medical ﬁles is physician-
dependent; furthermore given the study characteristics, the
variables were not systematically recorded for assessment
and analysis. Both of these circumstances would result in
greater data variability and less reliability. For this reason, we
only collected automatically recorded laboratory parameters
(from the laboratory database), demographic data and, if
available, the pathologic history of CRF (albuminuria, which,
although it is an important parameter for assessing CKD, wasnot contemplated because many  patients did not have this
information available). In fact, it was observed that only 67.7%
of patients with conﬁrmed CRF had the CRF diagnostic code
among their list of diseases, this code is observed in only
one-third of patients with RF (acute or chronic) and even in
some patients with maintained GFR. This demonstrates not
only the insufﬁcient use of the CRF code (whether diagnosed
or not) but also the poor use of the term because the time
criterion that deﬁnes it is often not considered.
As for the control of CV risk factors, only half of the patients
with CRF presented c-LDL levels <100 mg/dL and only 15.5%
had <70 mg/dL. Furthermore, patients with severe CRF pre-
sented most favourable lipid levels (Table 3). This could reﬂect
how more  intense therapies are applied in advanced disease
stages and in patients who, theoretically, are receiving nephro-
logical treatment. These results illustrate the need to increase
the awareness of PC physicians about the importance of diag-
nosing the disease ﬁrst of all, treating it second of all, and
then properly recording it in patient ﬁles so that CV risk can
be estimated along with the potential risk for presenting other
complications and adverse pharmacological effects. Progress
has been made in this direction in recent years and, as the
PC setting is essential for the detection and control of CKD,
clear criteria have been established for the management and
referral of these patients to specialists in nephrology.20
Last of all, the prevalence of ORD was evaluated. This
is a frequent situation in daily practice because renal func-
tion is generally estimated according to plasma creatinine
levels alone (which is favoured by the fact that the labora-
tory does not automatically offer GFR estimation results using
the formulas available). As we  have commented previously,
these levels varied due to several factors (age, sex, weight
or muscle mass, diet, etc.) so that the mathematical rela-
tionship between these 2 variables is an hyperbola.21 Studies
done in different healthcare settings report ORD prevalences
that ranged from 26 to 49.3% of all RF cases (given that said
studies have the same limitations that RF prevalence studies
demonstrate). It was also observed to affect almost exclu-
sively seniors and women3–7,22 who were generally in stage
3. In the series, and coinciding with these ﬁndings, ORD rep-
resents one-third of all RF cases. In CRF patients, however, it
is interesting that just 5.3% presented ORD, although in both
circumstances it still almost exclusively affects women and
patients of older age.The fact that in women GFR < 60 mL/min was detected with
creatinine levels of 0.9 mg/dL leads us to believe that the cur-
rent threshold for normal (1.2 mg/dL) is not very sensitive for
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F screening. Thus, these results suggest: (a) GFR should be
stimated using formulas, when possible, which are especially
alid in women and in seniors (a population that is usually
olymedicated and in treatment with drugs that are suscep-
ible to dose adjustments or contraindicated in RF)7; and, (b)
iven the frequency with which renal function is assessed by
erum creatinine, the threshold for normal should be lowered
o avoid errors and situations of ORD, especially in women (for
he creatinine determination method of this study, values of
0.9 mg/dL should be considered normal).
imitations
ossible study limitations include: (a) this is a prevalence study
n patients treated at our BHD health center who had at least
ne blood test, which may have led to selection bias and an
verestimation of the actual prevalence of kidney disease; (b)
ystematic lab tests at 3-month intervals were not available
or this study, and mean time transpired between tests was
 little more  than one year; (c) the MDRD formula used to
stimate GFR has a series of limitations itself, including being
ased on serum creatinine levels, whose determination is not
tandardised.
onclusions
onsidering the results of this present study and previ-
us reports by other authors, it seems obvious that, in
rder to assess the actual scope of renal disease in Spain,
ew prevalence studies are necessary for RF, CRF and ORD.
he comparison and analysis of the prevalences found in
his series demonstrate signiﬁcant variability depending on
he number of creatinine determinations studied and, like-
ise, the important limitations of the studies published to
ate.
Furthermore, in the battle against CKD, it is fairly clear
hat PC physicians play an essential role in the detection
which in most cases could be a mild-moderate stage of
RF), control and treatment of these patients. Proper patient
anagement also involves correctly recording this pathologic
istory in patient medical ﬁles because these data are of
rognostic and therapeutic importance. The MDRD formula
s a good tool for determining GFR; in addition to estimating
RF severity, it is also able to estimate the CV risk of these
atients.
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